Gasper J. LaRosa

Gasper LaRosa is a trial attorney who has represented plaintiffs and defendants in high profile patent infringement cases involving pharmaceutical products, medical devices, chemical manufacturing processes, and business methods. He has tried patent cases to juries and to the bench in several federal district courts. In addition, Gasper has experience representing clients as lead counsel in USPTO post-grant proceedings.

Gasper's practice focuses particularly on Hatch-Waxman (ANDA), biosimilar (BPCIA), and other patent litigation on behalf of pharmaceutical and biotechnology companies. He has represented major pharmaceutical companies in the enforcement of patents covering some of the world’s most successful drug products and drug delivery systems. His representations include litigations concerning Butrans® (buprenorphine patch, extended release), OxyContin® (oxycodone hydrochloride extended release tablets), Androgel® (transdermal testosterone replacement therapy), Thalomid® (a treatment of multiple myeloma and erythema nodosum leprosum), Revlimid®, Skelaxin® (a muscle relaxant), Avinza® (an extended release morphine sulphate pain reliever), Univasc® and Uniretic® (ACE inhibitors). [1]